Certain information has been omitted from this exhibit in places marked “[***]” because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed. In addition, certain personally identifiable information...Credit Agreement • February 28th, 2022 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT is entered into as of December 7, 2020 among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), the Guarantors (defined herein) listed on the signature pages hereto and from time to time party hereto, the Lenders (defined herein) from time to time party hereto and ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, a Delaware limited partnership, as Administrative Agent for the Lenders (each as defined below).
Certain personally identifiable information has been omitted from this exhibit in places marked “[***]” pursuant to Item 601(a)(6) under Regulation S-K. BIOCRYST PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 28th, 2022 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of November 19, 2021 by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (the “Investor”). Any capitalized terms used but not defined herein shall be as defined in the 2021 PSA (as defined below).
